Indaptus Therapeutics Files S-1 for Security Registration

TL;DR

Indaptus Therapeutics just filed an S-1, looks like they're gearing up to sell stock.

AI Summary

Indaptus Therapeutics, Inc. filed an S-1 registration statement on September 12, 2024, to register securities under the Securities Act of 1933. The company, formerly known as Intec Parent Inc. until April 14, 2021, is incorporated in Delaware and headquartered at 3 Columbus Circle, New York, NY. The filing indicates a primary SIC code of Pharmaceutical Preparations (2834).

Why It Matters

This S-1 filing is a crucial step for Indaptus Therapeutics as it signals their intent to offer securities to the public, potentially raising capital for their operations in the pharmaceutical sector.

Risk Assessment

Risk Level: medium — As an S-1 filing, it indicates a company is preparing to go public or raise capital, which inherently carries risks associated with market reception and regulatory hurdles.

Key Numbers

• 2834 — SIC Code (Indicates business in Pharmaceutical Preparations)
• 86-3158720 — IRS Number (Employer Identification Number)

Key Players & Entities

• Indaptus Therapeutics, Inc. (company) — Registrant
• September 12, 2024 (date) — Filing Date
• Securities Act of 1933 (legal_document) — Governing Act
• Intec Parent Inc. (company) — Former Company Name
• April 14, 2021 (date) — Name Change Date
• Delaware (location) — State of Incorporation
• 3 Columbus Circle, 15th Floor, New York, NY 10019 (address) — Principal Executive Offices
• Jeffrey A. Meckler (person) — Chief Executive Officer
• Peter N. Handrino (person) — Agent for Service

FAQ

Key Financial Figures

• $0.01 — 3,837 shares of common stock, par value $0.01 per share, of Indaptus Therapeutics Inc
• $1.54 — stock on the Nasdaq Capital Market was $1.54 per share. Investing in our securitie
• $1.70 — ely exercisable at an exercise price of $1.70 per share and expire five years from th
• $1 — are of common stock and one warrant was $1.825, resulting in gross proceeds of app
• $3.0 m — ting in gross proceeds of approximately $3.0 million, before deducting placement agent
• $0.5 million — expenses in the amount of approximately $0.5 million. Company Information Our principal
• $2.8 million — ll, the proceeds would be approximately $2.8 million. We currently intend to use the net pro

Filing Documents

• forms-1.htm (S-1) — 337KB
• ex5-1.htm (EX-5.1) — 16KB
• ex23-1.htm (EX-23.1) — 4KB
• ex107.htm (EX-FILING FEES) — 17KB
• ex5-1_001.jpg (GRAPHIC) — 18KB
• 0001493152-24-036059.txt ( ) — 401KB

RISK FACTORS

RISK FACTORS 4 SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS 5

USE OF PROCEEDS

USE OF PROCEEDS 6 DIVIDEND POLICY 7 SELLING STOCKHOLDER 8 DESCRIPTION OF SECURITIES 10 PLAN OF DISTRIBUTION 15 LEGAL MATTERS 17 EXPERTS 17 WHERE YOU CAN FIND MORE INFORMATION 17 INCORPORATION BY REFERENCE 18 i ABOUT THIS PROSPECTUS This prospectus is part of a registration statement that we filed with the Securities and Exchange Commission (the “SEC”). As permitted by the rules and regulations of the SEC, the registration statement filed by us includes additional information not contained in this prospectus. You may read the registration statement and the other reports we file with the SEC at the SEC’s website or its offices described below under the heading “Where You Can Find More Information”. You should rely only on the information contained or incorporated by reference in this prospectus. We have not, and the selling stockholders have not, authorized anyone to provide you with different information. If anyone provides you with different or inconsistent information, you should not rely on it. The distribution of this prospectus and sale of these securities in certain jurisdictions may be restricted by law. We are not making an offer to sell these securities in any jurisdiction where the offer or sale is not permitted. Persons in possession of this prospectus are required to inform themselves about and observe any such restrictions. The information contained in this prospectus and the documents incorporated by reference in this prospectus that we have authorized for use in connection with this offering, is accurate only as of the date of those respective documents regardless of the time of delivery of this prospectus when any sale of our securities occurs. Our business, financial condition, results of operations and prospects may have changed since those dates. You should read this prospectus and the documents incorporated by reference in this prospectus in their entirety, before making an investmen

View Full Filing

View this S-1 filing on SEC EDGAR